Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Disitamab vedotin |
Trade Name | |
Synonyms | RC48|Hertuzumab-vc-MMAE|RC-48 |
Drug Descriptions |
Disitamab vedotin (RC48) is an antibody-drug conjugate comprising a monoclonal antibody that targets HER2 (Hertuzumab) linked to the cytotoxic drug MMAE, which delivers the cytotoxic agent to HER2-expressing tumor cells, potentially resulting in increased cell death (PMID: 27509865, PMID: 31877330). |
DrugClasses | HER2 (ERBB2) Antibody 76 |
CAS Registry Number | 2136633-23-1 |
NCIT ID | C169918 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cisplatin + Disitamab vedotin | Cisplatin Disitamab vedotin | 0 | 0 |
Disitamab vedotin | Disitamab vedotin | 0 | 3 |
Disitamab vedotin + Pembrolizumab | Disitamab vedotin Pembrolizumab | 0 | 2 |
Disitamab vedotin + Toripalimab-tpzi | Disitamab vedotin Toripalimab-tpzi | 0 | 0 |
Disitamab vedotin + Tucatinib | Disitamab vedotin Tucatinib | 0 | 1 |